Supernus Pharmaceuticals, Inc. (SUPN) Stock Grade

About Supernus Pharmaceuticals, Inc.'s fundamentals

Supernus Pharmaceuticals is a $2.8 billion specialty and generic drug manufacturer with modest revenue growth of 8.6% year-over-year, though the company reported a net loss with a negative net margin of -5.4% in its latest annual period. Despite the accounting losses, the company maintains positive free cash flow, suggesting operational cash generation exceeds its paper losses. The company does not pay a dividend and lacks sufficient profitability metrics for traditional valuation ratios like P/E and return on equity.